Podcasts about Eli Lilly

Plus, Eli Lilly reports dramatic weight loss in a clinical trial of a next-generation obesity drug. And the U.S. trade deficit fell to a five-year low in September. Pierre Bienaimé hosts. Sign up for WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Welcome back for season 3 of The Big Podcast. Today Shaq welcomes NBA legend Carmelo Anthony and together they talk players in the NBA today, why Steph and Luka are unstoppable & much more. Make sure you subscribe so you never miss an episode of The Big Podcast.Download DraftKings Pick6 and use code BIGPODShaq-A-Licious. New fun shapes + flavors are out now: XL Sweets meets XL Style. Shaq-A-Licious Sneakers.It's what they thought that counts. Shop jcp.com. Yes, JCPenney!Visit DontSleepOnOSA.com to Learn More.Look to Lunazul Tequila – 100% Agave Tequila…Where tradition outshines trends….available at a liquor store near you. https://lunazultequila.com/ZipRecruiter. The smartest way to hire. Go to this exclusive web address to try ZipRecruiter for FREE: http://ZipRecruiter.com/BIGSubscribe to The Big Podcast YouTube Channel to watch more episodes!Follow us on all platforms: https://linktr.ee/bigpodcastChapters:00:00 Intro02:15 Shaq & Melo's different approaches to analyst job09:30 Shaq on “Sacramento Queens”12:00 DraftKings segment14:05 DraftKings ad14:45 Eli Lilly ad15:20 Who's got a similar game to Melo's?18:30 Why Steph and Luka are so unstoppable21:25 Could Shaq play in today's NBA?22:35 The brilliance of the Triangle Offense25:45 Wemby vs Draymond27:25 Passing on knowledge to his son31:35 Shaq-a-licious ad32:05 Lunazul ad32:55 Transition to Business Man37:40 Melo opens up about Phil Jackson45:05 Hilarious Stevie Wonder stories47:20 JCPenney segment48:45 JCPenney ad49:37 ZipRecruiter ad51:05 Big Men Alliance reunion53:35 NBA Scorers Mt. Rushmore54:45 Why Melo doesn't like the GOAT debate59:00 Should Steph be on the list?01:00:20 China fanbase01:03:00 Why comedy's so important to Shaq01:07:05 EndingGambling Problem? Call 1-800-GAMBLER. Help is available for problem gambling. Call (888) 789-7777 or visit ccpg.org (CT).18+ (19+ AL/NE, 21+ AZ/MA/VA). Valid only where Pick6 operates, see dkng.co/pick6states. Void in NY, ONT, and where prohibited. Eligibility restrictions apply. 1 per new DraftKings customer. First $5+ paid Pick Set to receive max. $50 issued as non-withdrawable Pick6 Credits that expire in 14 days (336 hours). Ends 1/25/26 at 11:59 PM ET. Terms: pick6.draftkings.com/promos Sponsored by DraftKings#nba #lakers #shaq #bigpod #basketball #bigshaq #bigpodcast #comedy #humor #miketyson #boxing #jakepaul Hosted on Acast. See acast.com/privacy for more information.

The price of Warner Brothers Discovery could creep higher as both Paramount and Netflix ready to up their offers in a possible bidding war, computer memory maker and Nvidia supplier SK hynix is considering listing shares in the U.S., Disney is nominating former Apple executive Jeff Williams to join its board, Eli Lilly will spend $6 billion to build a manufacturing plant in Alabama, and European company Delivery Hero says its evaluating its strategic options after a stock slump. Squawk Box is hosted by Joe Kernen, Becky Quick and Andrew Ross Sorkin.  Follow Squawk Pod for the best moments, interviews and analysis from our TV show in an audio-first format. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

A bill that would redraw Indiana's congressional map to benefit Republicans passed through its second reading Thursday after hours of argument. A state-mandated task force chaired by Mayor Joe Hogsett has advanced two proposals that could fundamentally change how Indianapolis schools are governed. Attorney General Todd Rokita and Secretary of State Diego Morales say a federal agency review found 21 noncitizens have cast ballots in Indiana elections, along with 165 noncitizens who registered to vote in the state. Indiana University and Eli Lilly are working together to expand clinical trials. Amazon founder Jeff Bezos and his wife, Lauren Sánchez Bezos, awarded a grant to an Indianapolis nonprofit fighting homelessness. Want to go deeper on the stories you hear on WFYI News Now? Visit wfyi.org/news and follow us on social media to get comprehensive analysis and local news daily. Subscribe to WFYI News Now wherever you get your podcasts. WFYI News Now is produced by Zach Bundy, with support from News Director Sarah Neal-Estes.

If you'd like your question answered on next month's episode, call/text 469-213-6381 and leave us a voicemail/text.Each month on Last Month In Healthcare, producer Nathaniel joins me to discuss the previous month's podcasts, headlines, and listener-submitted questions. This month, we're joined by Chris Hamilton! We talk about the J&J lawsuit being dismissed, Eli Lilly switching PBMs, AI in healthcare, and much more. We also play a Christmas game called Home Alone: The Wet Bandit's Bills, where Chris and I try to guess the average hospital price for the injuries incurred by the bandits from the Home Alone films.Chapters: 0:00 - Intro0:42 - J&J Lawsuit Dismissed9:20 - Eli Lily Switches PBMs11:17 - New FDA Rules On Biosimilars16:36 - AI Adoption In The Healthcare Industry25:21 - Survey On At-Home Medical Devices29:57 - Home Alone: The Wet Bandit's Bills42:32 - Ask Spencer AnythingSources: https://www.healthcaredive.com/news/fda-biosimilars-guidance-speed-development-comparative-efficacy-studies/804191/https://www.beckerspayer.com/legal/judge-dismisses-lawsuit-accusing-jj-of-mismanaging-employee-drug-benefits/?origin=PayerE&utm_source=PayerE&utm_medium=email&utm_content=newsletterhttps://www.healthcare-brew.com/stories/2025/11/25/eli-lilly-switches-big-3-pbm-alternative-transparent-rivalhttps://www.fiercehealthcare.com/health-tech/amid-shutdown-health-it-vendors-say-hospitals-are-cutting-back-spendinghttps://www.techtarget.com/virtualhealthcare/news/366633680/Survey-At-home-monitoring-devices-popular-affordablehttps://pubmed.ncbi.nlm.nih.gov/41265449/https://www.emarketer.com/content/ai-spending-healthcare-outpaces-overall-us-economy-

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/WZW865. CME/AAPA credit will be available until December 4, 2026.Guiding Patients Through Cardio-Renal-Metabolic Conditions: The Essential Role of Primary Care Clinicians In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/WZW865. CME/AAPA credit will be available until December 4, 2026.Guiding Patients Through Cardio-Renal-Metabolic Conditions: The Essential Role of Primary Care Clinicians In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.Disclosure information is available at the beginning of the video presentation.

Big tech is stumbling while pharma stocks surge, what does that mean for markets heading into 2026? In this episode, Anthony and Piers unpack why Nvidia, Microsoft, and Amazon are dragging, while Eli Lilly and Merck lead a surprising rotation. They also explore shifting Fed rate cut expectations, conflicting US labor data, and what it all signals for the S&P 500's next move.We also break down Deutsche Bank's “triple whammy” dollar call, Trump's Fed chair pick, and why a yen carry trade unwind could shake crypto markets. Plus, UK PMI surprises and pound strength, are brighter days ahead for the UK economy? Tune in for easy-to-follow macro insights this week!(00:00) Topics & Listener Shoutouts(02:51) Big Tech Wobble, Pharma Surge(09:16) Fed Cut Expectations & Labour Data(18:27) Trump's Fed Pick & Market Reaction(24:23) Deutsche Bank US Dollar Call(30:07) Yen Carry Trade & Crypto Risk(36:01) UK Budget Bounce & PMI Surprise*****Last chance to join our in-person Finance Bootcamp in London 15-19 December 2025. As part of our podcast community, you can use the code BOOT500 at checkout for a £500 discount.

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über das Microsoft-Barometer und seine Folgen, das Inditex-Luxusproblem und gute Stimmung bei Salesforce. Außerdem geht es um Eli Lilly, AbbVie, Johnson & Johnson, Novo Nordisk, AstraZeneca, Abbott Laboratories, UnitedHealth Group, Bristol Myers Squibb, Dexcom, Align Technology, ResMed, Hims & Hers, JD Health International, iRhythm Technologies, Pro Medicus, Oscar Health, Xtrackers MSCI World Health Care (WKN: A113FD), Amundi S&P World Health Care Screened (WKN: A3DSTC), Franklin Future of Health and Wellness (WKN A3EFKW), Global X Telemedicine & Digital Health (WKN A2QKQ1), Xtrackers MSCI Genomic Healthcare Innovation (WKN: DBX0R2), Agilent, Roche, Vertex, Microsoft, Meta, Alphabet, Amazon, Nvidia, Salesforce, SAP, Snowflake, Inditex, H&M, Next, LVMH, Hermès, Aumovio, TKMS, Hellofresh, Gerresheimer, Ottobock, Tonies, PSI Software, Verbio, LPKF, Stratec, Thyssenkrupp Nucera, Procredit, Amadeus Fire, Bayer, BASF, Corteva, Syngenta, Formycon und PNE. Die aktuelle "Alles auf Aktien"-Umfrage findet Ihr unter: https://www.umfrageonline.com/c/mh9uebwm Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Winner of the CTP Cup for IBIT Announcing the participants for the CTP Cup 2025 Calling a Code Red! Sam Altman’s declaration PLUS we are now on Spotify and Amazon Music/Podcasts! Click HERE for Show Notes and Links DHUnplugged is now streaming live - with listener chat. Click on link on the right sidebar. Love the Show? Then how about a Donation? Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter Interactive Brokers  Warm-Up - Winner of the CTP for IBIT - Announcing the participants for the CTP Cup 2025 - Calling a Code Red! Sam Altman's panic - Here come the Tariff lawsuits - - Smart Toilets are a thing (And learning the Bristol Scale) Markets - Horses can smell the barn.... Seasonal Trends - PR Teams - full throttle - (This is their Social Media) - Tax planning over the next couple of weeks may see some selling into year end Impressive Results - India's economy grew at a faster-than-expected pace of 8.2% in the quarter ended September against a forecast of 7.3% in a Reuters poll and 7.8% expansion in the previous quarter, data released last Friday showed. - The Indian government has cut consumer taxes on hundreds of items and implemented long-delayed labour reforms in the last three months as it tries to keep the domestic economy strong in the face of global uncertainties. - Strongest in 6 quarters - Economists said stockpiling for the festive season as well as expedited exports ahead of the 50% tariff deadline on August 27 might have contributed to the quarterly growth figures. - Manufacturing output rose 9.1% in the quarter ending in September from a year earlier against growth of 7.7% a quarter ago, while construction expanded 7.2% year-on-year from 7.6% a quarter ago. NVDA Spreading Out - Nvidia on Monday announced it has purchased $2 billion of Synopsys common stock as part of a strategic partnership to accelerate computing and artificial intelligence engineering solutions. - As part of the multiyear partnership, Nvidia will help Synopsys accelerate its portfolio of compute-intensive applications, advance agentic AI engineering, expand cloud access and develop joint go-to-market initiatives, according to a release. - Nvidia said it purchased Synopsys' stock at $414.79 per share (Now at $445) Amazon Ultra Fast Service - The parent company of Instacart fell nearly 4% after Amazon said it's testing “ultra-fast” delivery of groceries in Seattle and Philadelphia. - These deliveries take about 30 minutes or less, said Amazon. - Doordash and other delivery companies stocks also fell. Microstrategy - Strategy - Stock has been under pressure - Who knows what the company actully does anymore - Leverage Bitcoin play - issuing massive debt and convertibles to but Bitcoin - Stock down 39% this year and 52% 1 -year (Up 400% in the last 5 years) -Bitcoin dropped below $87k this week before staging a recovery bounce. Devil's Metal - Silver has outpaced gold in 2025, with a growth of about 71%, compared to gold's 54%. - Silver mine production has been decreasing for the past ten years, especially in Central and South America, due to mine closures, resource depletion and infrastructure challenges. - While industrial demand for silver is expected to decline slightly in 2025, the metal is increasingly used in electric vehicles, for AI components and in photovoltaics. - Some people are saying that people were having to transport silver by plane rather than on cargo ships to meet delivery demand INTERACTIVE BROKERS Check this out and find out more at: http://www.interactivebrokers.com/ Some Trump Updates: - Reiterates his view that Chair Powell should reduce rates. - Says he's negotiating with Democrats on healthcare. - Plans to give refunds out of collected tariffs. Crying Game - SoftBank Group founder Masayoshi Son on Monday downplayed the decision to offload the conglomerate's entire Nvidia stake, saying he “was crying” over parting with the shares. - Speaking at a forum in Tokyo Monday, Son addressed SoftBank's November disclosure that the firm had sold its holding in the American chip darling for $5.83 billion. - According to Son, SoftBank wouldn't have made the move if it didn't need to bankroll its next artificial intelligence investments, including a big bet on OpenAI and data center projects. Are Stocks Overvalued? CAPE RATIO Consumers... Consumer Confidence CODE RED -  Chief executive Sam Altman reportedly declared a “code red” on Monday, urging staff to improve its flagship product ChatGPT, an indicator that the startup's once-unassailable lead is eroding as competitors like Google and Anthropic close in. - In the memo, reported by the Wall Street Journal and The Information, Altman said the company will be delaying initiatives like ads, shopping and health agents, and a personal assistant, Pulse, to focus on improving ChatGPT. This includes core features like greater speed and reliability, better personalization, and the ability to answer more questions, he said. - Herein lies the problem with this entire tech market - what if ChatGPT fades to the sideline with $1.5Trillion promised over the next 5-7 years? - Remember, Google declared a Code Red after the arrival of ChatGPT. AI Takeover - Massachusetts Institute of Technology on Wednesday released a study that found that artificial intelligence can already replace 11.7% of the U.S. labor market, or as much as $1.2 trillion in wages across finance, health care and professional services. - The study was conducted using a labor simulation tool called the Iceberg Index, which was created by MIT and Oak Ridge National Laboratory. - The index simulates how 151 million U.S. workers interact across the country and how they are affected by AI and corresponding policy. Costco Sues - Costco filed a lawsuit asking for a full refund of tariffs the warehouse club giant has paid since President Donald Trump imposed “reciprocal” and “fentanyl” tariffs earlier this year. - Costco sued the Trump administration to get a full refund of new tariffs it paid so far this year, and to block those import duties from continuing to be collected from the retail warehouse club giant as a Supreme Court case plays out. - Costco is worried that it would lose the money even if the Tariffs were deemed illegal. Fat Cutting -  Eli Lilly said it is lowering the cash prices of single-dose vials of its blockbuster weight loss drug Zepbound on its direct-to-consumer platform, LillyDirect. - Starting Dec. 1, cash-paying patients with a valid prescription can pay $299 to $449 per month for Zepbound vials on LillyDirect, depending on the dose, down from a previous range of $349 to $499 per month. - The announcement comes just weeks after President Donald Trump inked deals with Eli Lilly and Novo Nordisk to make their GLP-1 drugs easier for Americans to access and afford. Smart Toilets - This year industry giants Toto Ltd. and Kohler Co. introduced smart toilets capable of analyzing what is in the bowl - Launched in August, the latest model in the Neorest line starts at roughly $3,200. - It uses an LED light and a sensor to read the shape, color, hardness and volume of stool as it drops, and sends data to a smartphone app in less than a minute. - Each toilet can support as many as six users — enough for most households — while some companies have bought multiple units for their employees. Toto aims to sell 7,300 units annually by 2028. - For now the stool-scanning Neorest is available only in Japan. - The app analyzes bowel movements against the Bristol scale, which is commonly used to diagnose constipation, inflammation or diarrhea, and offers simple recommendations such as eating more fiber and drinking more water, or even menu suggestions, like vegetable soup. Bristol Scale Feel Good - Entrepreneur Michael Dell and his wife, Susan, will deposit $250 in the individual investment accounts of 25 million American children in a $6.25 billion philanthropic pledge as part of the Trump administration's Invest America initiative. - $250 each child born after between 2015 and 2025 - The money will go to the accounts of children who live in ZIP codes where the median family's income is $150,000 or less, according to a spokesperson for the Dells. Love the Show? Then how about a Donation? Announcing the Winner for iShares Bitcoin Trust ETF (IBIT) Winners will be getting great stuff like the new "OFFICIAL" DHUnplugged Shirt! CTP CUP 2025 Here is the list of players: Jim Beaver Mike Kazmierczak Joe Metzger Ken Degel David Martin Dean Wormell Neil Larion Mary Lou Schwarzer Eric Harvey (2024 Winner) FED AND CRYPTO LIMERICKS See this week's stock picks HERE Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter

Show Notes In this episode of Develop This!, host Dennis Fraise sits down with Jason El Koubi, President and CEO of the Virginia Economic Development Partnership (VEDP), to explore how Virginia has earned — and maintained — its reputation as one of the best states for business. Jason shares how Virginia's nonpartisan approach to economic development ensures continuity, focus, and accountability. He dives deep into the Virginia Talent Accelerator Program, a national model for workforce training that has helped attract global leaders like AstraZeneca and Eli Lilly. From site readiness to speed-to-market, Virginia's economic playbook emphasizes agility, collaboration, and long-term talent development. Jason also discusses how the state is positioning itself for the industries of the future — including pharmaceutical manufacturing and artificial intelligence — all while doubling down on its goal to be America's Top State for Talent. If you're passionate about strategic, results-driven economic development, this episode offers a rare look inside a state model that works — and what other regions can learn from it.

Topics We Cover: 00:00 – New data from Harvard/Mass General may classify nearly 70% of adults as having obesity 03:00 – A new oral triple agonist shows record-setting absorption rates 07:00 – Fractal Health's Revita procedure: weight maintenance after stopping GLP-1s 12:00 – Zepbound vial prices drop (full breakdown by dose) 16:00 – Dave's personal experience switching off Mounjaro and intense hunger return 22:00 – Novo Nordisk's EVOKE/EVOKE+ Alzheimer's trial: what the data really means 29:00 – Why GLP-1 neurological research is just getting started 33:00 – Updates on access, partners, and major news coming soon for Medicare patients If you're on Wegovy, Mounjaro, Zepbound, Saxenda, Trulicity, or compounded versions, this episode gives you the insight and context you need to have more competent and confident conversations with your doctor. Bullet Point Summary of the Podcast Episode New Obesity Measurement Data (Harvard/Mass General Study) Harvard and Mass General propose adding waist circumference to BMI to better diagnose obesity. Traditional BMI misses key factors like muscle mass and body composition. Using the updated measure, Americans classified as obese jumps from ~43% to almost 69%. This means 7 out of 10 U.S. adults would now qualify as having the disease of obesity. Dave notes this validates many people who “feel” metabolically unwell despite a “normal” BMI. Reinforces his claim that “most people should be talking to their doctors about GLP-1s.” New Oral Triple Agonist (Ascletis – ASC41/ASC? Molecule) From Ascletis (A-S-C-L-E-T-I-S), developing an oral triple agonist targeting: GLP-1 GIP Glucagon Similar in mechanism to retatrutide, expected around 2027. Preclinical (animal) data show stunning results: Oral bioavailability of 4.2% 9× higher than tirzepatide 30× higher than oral semaglutide 6× higher than oral retatrutide 57× greater drug exposure than oral retatrutide Half-life ~56 hours Stronger receptor activation than retatrutide in vitro Suggests potential for the first powerful oral triple agonist—worth watching. ️ 3. Discussion of the Gray Market / TikTok Experience Dave briefly recounts losing his TikTok account and landing in an algorithm filled with teenagers promoting gray-market “retatrutide.” Expresses concern over unregulated peptide sales, especially to minors. Fractal Health's New Data – Weight Maintenance After Stopping GLP-1s New results from the Reveal One study (Fractal Health). Participants: lost 24% of body weight on GLP-1s → stopped injections → got one Revita procedure. At 6 months post-GLP-1 discontinuation: Weight changed only 1.5% (vs. ~10% regain in typical off-drug trials) HbA1c barely shifted Safety profile clean Suggests possible long-term weight maintenance without injections through gut mucosal re-lining. Dave describes his own recent attempt to switch drugs and significant hunger return. Food Noise & Biologic Hunger Dave discusses how stopping Mounjaro caused terrifying, primal hunger. Describes the distinction between: Food noise (brain-based thoughts) Hunger signals (biological/animalistic) Reinforces why many patients cannot maintain weight loss without support. Zepbound (Tirzepatide) Cash-Pay Price Reductions Eli Lilly drops cash-pay vial pricing: 2.5 mg: $349 → $299 5 mg: $499 → $399 7.5–15 mg: $499 → $449 Community feedback (informal poll): Most say still too high to leave compounded versions. Many would switch to branded if price hit $200–$300. Dave notes the Most Favored Nations agreement will push GLP-1 prices toward $250/month within 24 months. Alzheimer's Study (Novo Nordisk – EVOKE & EVOKE+) Oral semaglutide (Rybelsus, 14 mg) did not slow Alzheimer's clinical progression. Biomarkers improved but daily function and cognitive decline did not improve vs placebo. Important context: Oral Rybelsus is a weak form of semaglutide; stronger versions (like Wegovy 2.4 mg or upcoming high-dose oral Wegovy) not tested. Weight loss is not desirable in Alzheimer's patients, influencing drug selection. Dave emphasizes: This was a nearly $700M trial and an act of scientific courage. This is NOT the end of GLP-1 Alzheimer's research. Future molecules may target neurological pathways without suppressing appetite. Mentions Lilly's brenipatide, a GIP receptor agonist being developed for: Addiction Opioid dependency Possibly asthma ️ 8. Access, Cost, and Patient Empowerment Highlights Shed as a partner offering telehealth GLP-1 access. Notes many patients hide GLP-1 use from their primary care doctors. Reinforces OTP's mission: better, more honest conversations with clinicians. Shapa (Numberless Scale) & Dave's Personal Update Dave explains how the Shapa numberless scale helped him stay engaged during weight fluctuations. Finds stepping on “zones” (green/gray/blue) less emotionally damaging than numbers. Closing Notes Promises upcoming Eli Lilly savings card update. Encourages subscribing, liking, and enabling notifications for algorithm visibility. Thanks OTP community for amplifying patient-centric obesity medicine news. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The real "Turf Wars" in NYC, life skills young people wish they learned in school, Costco sues President Trump, North Korea has made Russian a required language class in schools, controversy over the US military's strike on a drug boat, Eli Lilly announced yesterday that it's lowering the cash prices of its weight-loss drugs, and a man has a decades old lighter removed from his stomach...

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll explore the latest advances and strategic moves shaping the industry, providing you with insights into how these developments might influence drug development and patient care.The pharmaceutical and biotech sectors are currently experiencing a wave of transformative changes. A significant development is the trade agreement between the United States and the United Kingdom, which excludes medicines from import tariffs. This strategic move, orchestrated by the Trump administration, is set to reduce costs and bolster investments in pharma sectors across both nations. By enhancing market accessibility, it aims to stimulate cross-border investment in pharmaceutical research and production.On the clinical front, Eli Lilly is making headlines by joining Novo Nordisk in reducing self-pay prices for its GLP-1 receptor agonist, Zepbound. This reflects a broader industry trend towards patient-centric pricing models aimed at improving affordability. With healthcare costs on the rise, these measures could ease financial burdens for patients requiring long-term medication regimens.Regulatory updates are also making waves, with the FDA planning stricter vaccine regulations under Dr. Vinay Prasad's leadership at the Center for Biologics Evaluation and Research (CBER). These updates come amid concerns over vaccine safety during COVID-19-related incidents, underscoring a commitment to maintaining public trust in vaccines. Regulatory scrutiny continues as Prasad focuses on COVID-19 vaccine safety in children amid reports linking 10 child deaths to vaccines via VAERS—emphasizing challenges interpreting safety data while highlighting the need for robust methodologies ensuring reliable causality conclusions.In corporate restructuring news, Valneva is streamlining its operations by closing a site and eliminating 30 roles. This move highlights an industry focus on optimizing resources to bolster vaccine development pipelines. Meanwhile, Microsize and Schedio's acquisition of Lonza's Swiss micronization plant underscores ongoing investments in advanced manufacturing technologies critical for high-quality pharmaceuticals.In ophthalmology, Belite Bio is advancing with promising Phase 3 results for tinlarebant in treating Stargardt disease—a rare genetic eye disorder. This success positions Belite to file for FDA approval, potentially expanding treatment options for this underserved patient population. Such advancements in targeted therapies emphasize the need for ongoing research in genetic disorders.Regeneron is betting $150 million on Tessera's gene writing technology targeting alpha-1 antitrypsin deficiency (AATD). This collaboration highlights the industry's growing interest in gene therapy as a frontier for treating rare diseases, marking a shift towards precision medicine where tailored genetic interventions offer hope for previously untreatable conditions. Regeneron's strategic move investing $275 million partnering with Tessera exploring gene editing capabilities—focusing on TSRA-196 targeting the SERPINA1 gene linked to AATD showcases potential advancing therapeutic options for genetic disorders through gene editing technologies offering new disease treatment avenues.AI-driven platforms were spotlighted at RSNA 2025 by industry leaders such as GE Healthcare, Philips, and Siemens. These innovations promise to revolutionize radiological workflows by enhancing diagnostic accuracy and operational efficiency through AI integration. As AI continues to permeate healthcare technologies, its potential to transform diagnostic processes marks a significant leap towards personalized medicine.Akebia Therapeutics' acquisition ofSupport the show

The first trillion-dollar healthcare company, a $298M longevity round, and a telehealth CEO headed for federal sentencing. Last month had range.Today on the show, Halle and Michael sort through the biggest December stories shaping the year ahead, from runaway longevity funding to a telehealth scandal headed for federal sentencing.We cover:

The Rockefeller Foundation has officially partnered with Beast Philanthropy, the organization run by Jimmy Donaldson, or MrBeast, the world's so-called #1 creator/influencer. According to a joint press release, the “strategic partnership is designed to meet young people where they are—online—and channel their desire for purpose into meaningful global action.” The partnership intends to promote global development, poverty alleviation, and sustainable impact. Billionaire Les Wexner, named extensively alongside Jeffrey Epstein, also runs a foundation looking to advocate the same goals, with emphasis on LGBT, climate, and racism. Wexner's foundation was not only funded with large sums of money from people like Epstein, but his entire wealth, upon which the foundation is constructed, was built on his being possessed by a demon named dybbuk, which he documents in a 1985 interview. In his own words.Back in the 1940s, the Rockefeller Foundation also financed a man named Alfred Kinsey, a reported homosexual who had a keen interest in sexuality and taboo sexual practices. In fact, Kinsey is considered the founder of the sexual revolution in the United States, just as Magnus Hirschfeld, who ran the world's first trans clinic, was the leader of the same movement in 1920s Germany. Other than his own sexuality, and an interest in pedophiles and sexual contact with children in general, Kinsey was inspired by none other than another Beast named Aleister Crowley, the sexual deviant, who was an agent of British Intelligence as much as Epstein was an agent of Israel-US intelligence. And according to a declassified CIA document, “Foundation Support for Research in the fields of Behavioral Sciences,” the CIA paid the Rockefeller Foundation, among others, large sums of money to conduct research in areas like “parapsychology” and studies on groups of “gifted individuals,” programs that often involved children, for which the television show Stranger Things was inspired in part. In 2024 the U.S. National Security Archive published a document collection highlighting the “CIA and the Behavioral Sciences: Mind Control, Drug Experimentation and MKULTRA,” and behind that researcher was the funneling of money to foundations like Rockefeller. The legacy of these experiments connects to the Kubark Counterintelligence Interrogation report from 1963 which discussed using psychological techniques, including fear, threats, and pain, along with narcotics and coercion, to compel compliance. Considering that drug companies like Eli Lilly played a role in distributing the CIA enough drugs for its experiments, it makes perfect sense how both in the US and UK not only were influencers paid by the government to promote corporate products, but Yale University set out the psychological messaging to coerce people into taking vaccines with threats of “trust the science,” “embarrassment,” “anger,” and “guilt,” while the UK literally employed fear campaigns to “frighten the pants off everyone,” as per Matt Hancock, former health secretary. Cabinet secretary Simon Case replied to that comment with “the fear/guilt factor.”The Tavistock Institute - Foundation is an extension of Magnus Hirschfeld's Institute of Sexual Science today. In 2019 Marcus Evans, one of the foundation's governors, resigned, accusing management of having an “overvalued belief” in the exercise of Gender Identity Development Service. Parents likewise accused the organization of “fast-tracking” young people into changing gender.  We can see in all of these cases the a plan to “meet young people where they are—online—and channel their desire for purpose into meaningful global action,” is a recruitment campaign to create “social justice warriors” and “revolutionaries,” or rather what former Soviet journalist Yuri Bezmenov said: demoralize, destabilize, and create ongoing crises that can be normalized to chance the social order.  The announcement also comes just a few days before the third (first, second) and most direct Fort Bragg psychological warfare video was released stating how in psy-war, “we are everywhere.” So, how do you fight these invisible enemies? Who is like unto the beast?*The is the FREE archive, which includes advertisements. If you want an ad-free experience, you can subscribe below underneath the show description.WEBSITEFREE ARCHIVE (w. ads)SUBSCRIPTION ARCHIVE-X / TWITTERFACEBOOKINSTAGRAMYOUTUBERUMBLE-BUY ME A COFFEECashApp: $rdgable PAYPAL: rdgable1991@gmail.comRyan's Books: https://thesecretteachings.info - EMAIL: rdgable@yahoo.com / rdgable1991@gmail.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-secret-teachings--5328407/support.

From Wall Street to Main Street, the latest on the markets and what it means for your money. Updated regularly on weekdays, featuring CNBC expert analysis and sound from top business newsmakers. Anchored and reported by CNBC's Jessica Ettinger. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

大家週ㄧ愉快！本集節目為台灣時間12/1的節目 Apple Podcast訂閱最大優惠一個月免費試聽，現在加入就抽Kobo Libra Colour! 如何開啟Podcast訂閱服務 Patreon訂閱往這邊走 免費訂閱通勤精釀電子報 裸辭倒數30天計劃 合作邀約請聯繫：onthewaytowork2020@gmail.com IG: @onthe_waytowork https://www.instagram.com/onthe_waytowork/ Powered by Firstory Hosting

Brandon is out again! Briefly cover the OPEC oil output decision and how the Ukraine war is still affecting prices. Also the monster that Eli Lilly is becoming and whether they are a buy or not.

In this weekend deep dive, we break down how a 149-year-old pharma company from Indianapolis reinvented itself through GLP-1 weight-loss drugs like Mounjaro and Zepbound, overtook Novo Nordisk, and became one of Wall Street's hottest stocks. We cover Lilly's history from insulin to Prozac, the explosive growth of its weight-loss franchise, the coming pill that could unlock an even bigger market, and the risks ahead. Is the trillion-dollar valuation just the start, or is the stock already priced for perfection?

Welcome back to Ozempic Weight Loss Unlocked, the podcast where we explore the latest breakthroughs in weight loss medications and metabolic health. I'm your host, and today we're diving into some fascinating developments that are reshaping the entire landscape of obesity treatment.Let's start with some exciting news. Eli Lilly has just announced results from a Phase 2 trial of a groundbreaking new medication called eloralintide. This once-weekly injectable showed remarkable results, with participants losing between nine point five and twenty point one percent of their body weight over forty-eight weeks. For comparison, those on placebo only lost point four percent. What makes this particularly interesting is that eloralintide works differently than Ozempic and other popular medications. While those drugs mimic the gut hormone glucagon-like peptide one, eloralintide mimics a pancreas hormone called amylin. This difference in mechanism could be a game changer for people who don't respond well to existing treatments.The trial involved two hundred sixty-three adults and showed improvements beyond just weight loss. Participants experienced better waist circumference, blood pressure, lipid profiles, and reduced inflammation markers. Some patients even saw improvements in conditions like hypertension, sleep apnea, and osteoarthritis. The most common side effects were mild to moderate gastrointestinal symptoms and fatigue, which were dose-dependent. Eli Lilly plans to launch Phase Three clinical studies by the end of this year, and they're also exploring using eloralintide in combination with current glucagon-like peptide one medications.Now, speaking of the broader landscape, the glucagon-like peptide one market is booming. Twenty twenty-five is shaping up to be the leading year for glucagon-like peptide one trial activity, with over sixteen point four percent of all trials happening right now. The United States leads with thirty-four point one percent of these trials, followed by China at twenty-seven point two percent. Eli Lilly and Novo Nordisk remain the main players driving innovation in this space.However, listeners, not all recent news has been positive. Novo Nordisk's highly anticipated trials for semaglutide, the active ingredient in Ozempic, showed no slowing of Alzheimer's disease progression. The two large trials called evoke and evoke plus involved over three thousand eight hundred people and ran for two years, but the results were disappointing. While glucagon-like peptide one drugs have shown protective effects in animal studies and some preventive benefits, halting neurodegeneration once it's already started appears to be a different challenge altogether. Researchers are still analyzing the data to see if there were any anti-inflammatory effects on the brain that might still prove valuable.And here's one more thing to watch. Ozempic two point zero is reportedly in development, with initial tests showing an average weight loss of ten point five percent compared to just two point two percent with older formulations. This suggests pharmaceutical companies continue innovating to provide even more effective options for our listeners.The key takeaway here is that weight loss medication science is evolving rapidly. We now have multiple mechanisms of action, combination therapies, and new formulations in the pipeline. What works best varies from person to person, which means having more options is genuinely beneficial.Thank you so much for tuning in to Ozempic Weight Loss Unlocked. Please subscribe to stay updated on these incredible developments in metabolic health and weight loss science. This has been a Quiet Please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

In Part 3, Hanna Svanbäck discusses the future of Alzheimer's care over the next five to 10 years, how trial design could be improved and reveals her opinion on the most exciting healthcare innovation on the horizon. Speaker bio Hanna Svanbäck is the Executive Director for Neuroscience, Eli Lilly, overseeing operations in the UK, Ireland and the Nordic countries. Hanna has over 15 years of experience at Lilly and is proud to lead the Neurosciences function given Lilly's long-standing commitment to advancing scientific innovation in this field. Hanna's passion for science and her dedication to utilising innovative approaches to enhance patient care are underpinned by her academic studies in Engineering Genomics and Biotechnology from the University of Umeå, Sweden and University of Manchester. Follow us on Instagram: @emj.gold

Il colosso farmaceutico Eli Lilly consolida il suo exploit borsistico in attesa del debutto della pillola anti obesità Learn more about your ad choices. Visit megaphone.fm/adchoices

Black Friday panic, Christmas chaos… and a derivatives-led global equity sell-off. In this episode of Talk Money To Me, Candice and Felicity zoom out from the noise and share six major investment themes set to shape portfolios in 2026 plus the ETFs, sectors and stocks they're watching right now.Recorded on 25 November 2025 following a sharp but non-fundamental global equity pullback driven by CTAs, futures activity and a VIX spike, the pair break down why retail investors have been buying the dip, not selling it and why the medium-term setup for equities remains constructive.They then reveal their 2026 Playbook, covering:⭐ Theme 1 – Mid-Duration Fixed Income & Floating RatesWhy the 3–5 year part of the curve, senior bank notes, floating-rate notes and diversified bond ETFs (like MQSD) are compelling defensive anchors heading into an uncertain rate environment.

Novo Nordisk can't keep up with demand for Ozempic and Wegovy, giving competitor Eli Lilly the edge in the GLP-1 market. And off-brand competitors continue to hammer the company's market position. Layoffs and board resignations signal that Novo Nordisk has entered a downward spiral. But with new leaders, acquisitions and deals, can they force a comeback?See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In Part 2, Hanna Svanbäck discusses the latest and most significant innovations in Alzheimer's care. She also considers whether healthcare systems are prepared for the anticipated surge in cases, and shares some positive news about prevention.  Speaker bio Hanna Svanbäck is the Executive Director for Neuroscience, Eli Lilly, overseeing operations in the UK, Ireland and the Nordic countries. Hanna has over 15 years of experience at Lilly and is proud to lead the Neurosciences function given Lilly's long-standing commitment to advancing scientific innovation in this field. Hanna's passion for science and her dedication to utilising innovative approaches to enhance patient care are underpinned by her academic studies in Engineering Genomics and Biotechnology from the University of Umeå, Sweden and University of Manchester.

Kara and Scott discuss X's new “About This Account” feature, which appears to show a wave of MAGA accounts posting from Russia, India, Nigeria, and beyond. They also unpack Marco Rubio denying reports that he privately called the Ukraine peace plan a Russian “wish list.” Plus, Google scores a major win with Gemini 3, Eli Lilly hits $1 trillion in market cap, and Marjorie Taylor Greene announces her exit from Congress. Watch this episode on the ⁠⁠Pivot YouTube channel⁠⁠.Follow us on Instagram and Threads at ⁠⁠@pivotpodcastofficial⁠⁠.Follow us on Bluesky at ⁠⁠@pivotpod.bsky.social⁠⁠Follow us on TikTok at ⁠⁠@pivotpodcast⁠⁠.Send us your questions by calling us at 855-51-PIVOT, or email Pivot@voxmedia.com Learn more about your ad choices. Visit podcastchoices.com/adchoices

Happy Thanksgiving! AgriNovus was proud to present the One Health Summit in partnership with BioCrossroads and Elanco this month at the company's newly opened global headquarters in Indianapolis. Please enjoy audio from this power panel including Elanco CEO Jeff Simmons, Corteva Agriscience CEO Chuck Magro, Eli Lilly CEO Dave Ricks, Purdue University President Mung Chiang and Indiana University President Pam Whitten. The panel was moderated by the Central Indiana Corporate Partnership (CICP) CEO Melina Kennedy to talk about the One Health opportunity and how best we can advance that here in the state.

This week, Isabel sits down with Hanna Svanbäck, Executive Director for Neuroscience, Eli Lilly, for an insightful discussion on the evolving landscape of Alzheimer's research. Together, they explore the latest breakthroughs, the challenges ahead and the strategies shaping the future of treatment and prevention. In Part 1 of the conversation, find out about Hanna's journey into neuroscience, her work in Alzheimer's spanning three key markets and how her teams overcome the inevitable hurdles of brain-based drug discovery. Speaker bio Hanna Svanbäck is the Executive Director for Neuroscience, Eli Lilly, overseeing operations in the UK, Ireland and the Nordic countries. Hanna has over 15 years of experience at Lilly and is proud to lead the Neurosciences function given Lilly's long-standing commitment to advancing scientific innovation in this field. Hanna's passion for science and her dedication to utilising innovative approaches to enhance patient care are underpinned by her academic studies in Engineering Genomics and Biotechnology from the University of Umeå, Sweden and University of Manchester.

Episode 720: Neal and Toby talk about Google's string of recent wins that resulted in its market value surpassing Microsoft. Then, America's affordability crisis seemed to be the one thing in common between the Trump and Mamdani meeting. Then, Eli Lilly hits $1 trillion in market value, first for a health care company. Meanwhile, “Wicked: For Good” smashes its target at the box office. Finally, a preview of what's coming in the week ahead.  Learn more at usbank.com/splitcard  Get your MBD live show tickets here! https://www.tinyurl.com/MBD-HOLIDAY  Subscribe to Morning Brew Daily for more of the news you need to start your day. Share the show with a friend, and leave us a review on your favorite podcast app. Listen to Morning Brew Daily Here:⁠ ⁠⁠https://www.swap.fm/l/mbd-note⁠⁠⁠  Watch Morning Brew Daily Here:⁠ ⁠⁠https://www.youtube.com/@MorningBrewDailyShow⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

The 5 things you need to know before the stock market opens today: airports expect the busiest day of the holiday travel week to be the Sunday after Thanksgiving, DOGE has been officially dissolved ahead of schedule, Kohl's is keeping its interim CEO on as CEO proper, the FBI is investigating a hack of SitusAMC, a technology vendor for real estate lenders, and Eli Lilly has become the first health care company to reach a $1 trillion market cap. Squawk Box is hosted by Joe Kernen, Becky Quick and Andrew Ross Sorkin.  Follow Squawk Pod for the best moments, interviews and analysis from our TV show in an audio-first format. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Cramer says the market for this pharmaceutical company will be far bigger than expected. Become a CNBC Investing Club member to go behind the scenes with Jim Cramer and Jeff Marks as they talk candidly about the market's biggest headlines. Signup here: cnbc.com/morningtakeCNBC Investing Club Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

New weight loss drugs may portend end of “Fat Acceptance” movement; Celebs and Southerners embrace GLP-1s; Trump clears path for more access to diet drugs; Mid- and late-life exercise slash dementia risk; “Ethicists” urge more tick-borne meat allergy to save planet—as alpha-gal syndrome claims first fatality; What's wrong with the melatonin study that claims it leads to heart failure? How to detox 9-11 first-responders? Can weekend warriors obtain same benefits as regular exercisers? 

Novo Nordisk hits a 4-year low, just days after rival Eli Lilly hits a $1T market cap milestone.Plus, some former high-flyers trading more down to earth. Is now the time to get in?  And, two unlikely names dominating the AI narrative now. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Novo Nordisk, leader européen de la pharma en 2023, a vu sa capitalisation chuter de 63 % en deux ans, dépassé par Eli Lilly et son Mounjaro. La concurrence s'intensifie sur le marché des traitements contre l'obésité, avec l'arrivée attendue de nouveaux acteurs comme Roche et Pfizer. Dans « La Story », le podcast d'actualité des « Echos », Pierrick Fay et Myriam Chauvot reviennent sur la bataille de l'obésité dans l'industrie pharmaceutique, bataille arbitrée aussi par Donald Trump.« La Story » est un podcast des « Echos » présenté par Pierrick Fay. Cet épisode a été enregistré en novembre 2025. Rédaction en chef : Clémence Lemaistre. Invitée : Myriam Chauvot (journaliste au service industries des « Echos »). Réalisation : Willy Ganne. Musique : Théo Boulenger. Identité graphique : Upian. Photo : Shutterstock. Sons : BFM Business, Loopsider, extrait « La cité de la peur », extrait «L'aile ou la cuisse», Extrait «Taxi 3». Retrouvez l'essentiel de l'actualité économique grâce à notre offre d'abonnement Access : abonnement.lesechos.fr/lastory Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

A new all-time high for Alphabet. How the stock is benefiting from the AI trade and what it means for the competition. Then the CEO of Tanger has a read on the consumer ahead of the holiday shopping season. Plus, Novo Nordisk shares fall following new trial data related to an Alzheimer's drug, while Eli Lilly tops a $1 trillion market cap. Citi breaks down what stocks to own. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Pharma giant Eli Lilly manufactures the ingredients for its weight-loss drug Mounjaro and its diabetes drug Zepbound in Kinsale, Co Cork.The Irish Fiscal Advisory Council (Ifac) has found that the unprecedented surge in Irish exports this year (exports to the US rose by 153 per cent to €71bn between January and May) was almost entirely driven by shipments of these ingredients.Ifac tracked about €36.4bn of this export surge to Indianapolis, where Eli Lilly is headquartered and where it has several manufacturing sites.The jump in exports is expected to see the Irish economy expand by almost 11 per cent in GDP terms this year, which is almost certain to make it the fastest-growing advanced economy in the world in 2025.So with such an over-reliance on foreign direct investment, notably in the pharma sector, at a time of tariff threats and uncertainty, how vulnerable is Ireland?Irish Times economics correspondent Eoin Burke-Kennedy explains.Presented by Bernice Harrison. Produced by Suzanne Brennan and Andrew McNair. Hosted on Acast. See acast.com/privacy for more information.

Mehr Experten-Interviews und tiefgehende Aktienanalysen findet ihr hier: oaws.de. Aktien hören ist gut. Aktien kaufen ist noch besser. Unser Partner Scalable Capital ist jetzt Bank und bietet euch dadurch jetzt noch bessere Konditionen. Mehr Infos findet ihr unter: scalable.capital/oaws. Eli Lilly = 1.000 Mrd. $, Foxconn kooperiert mit OpenAI und Alphabet, Ubisoft gibt Entwarnung bei wichtigem Tencent-Deal. Dazu gibt's Beef zwischen TSMC und Intel wegen Betriebsgeheimnissen und starke Zahlen von GAP. Fachkräftemangel und demografischer Wandel belasten die Wirtschaft. Und sie sind eine Gelegenheit für Amadeus Fire (WKN: 509310). Trotzdem ist die Aktie auf Rekordtief. Eine Chance? IBM (WKN: 851399) hat im Quanten-Bereich aktuell die Nase vorn. Das ist die Meinung von Daniel Volz von Kipu Quantum. Allerdings hat die Firma einige Challenger. D-Wave (WKN: A3DSV9), IonQ (WKN: A3C4QT) und Rigetti (WKN: A3DE3J) wollen vorbeiziehen. Diesen Podcast vom 24.11.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

Eli Lilly became the first drugmaker to reach a $1trn valuation Hosted on Acast. See acast.com/privacy for more information.

Der Chipriese hat in dieser Woche Zahlen präsentiert, die selbst die kühnsten Optimisten verblüfft haben. Doch statt einer Kursrallye herrscht Ernüchterung an der Börse. Die Wirtschaftsjournalisten Dietmar Deffner und Holger Zschäpitz streiten um die Gründe für das Börsenrätsel. Weitere Themen: Erster Pharmakonzern im Billionen-Club – was Eli Lilly anders als die Konkurrenz macht Nacht ohne Morgen – warum Analysten die Kursziele bei Lanxess weiter stutzen Dax mit größtem Wochenverlust seit April – was hinter dem Absturz steckt DEFFNER & ZSCHÄPITZ sind wie das wahre Leben. Wie Optimist und Pessimist. Im wöchentlichen WELT-Podcast diskutieren und streiten die Journalisten Dietmar Deffner und Holger Zschäpitz über die wichtigen Wirtschaftsthemen des Alltags. Schreiben Sie uns an: wirtschaftspodcast@welt.de Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutzerklärung: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

P.M. Edition for Nov. 21. It's mostly tech companies that have hit the milestone of a $1 trillion valuation. As WSJ Heard on the Street columnist David Wainer explains, Eli Lilly's entrance into this elite club is for a completely different reason: weight-loss drugs. Plus, New Mexico is one of the poorest states in the U.S., but it's planning to spend millions of dollars per year to be the first state to offer universal childcare. We hear from WSJ economics reporter Harriet Torry about how the plan will work, and what critics say. And now that the U.S. has presented its 28-point peace plan to Ukraine, President Trump says he expects an answer by Thanksgiving, leaving Ukrainian President Volodymyr Zelensky with what he calls a very difficult choice. Alex Ossola hosts. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Plus: Ukrainian President Volodymyr Zelensky says his country faces a difficult choice over the Trump administration's proposed plan to end the war. And New York Fed President John Williams, a key ally of Jerome Powell, says he sees room for an interest rate cut in the near term. Zoe Kuhlkin hosts. Sign up for WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Learn more about your ad choices. Visit megaphone.fm/adchoices

Carl Quintanilla, Jim Cramer and David Faber explored how investors should navigate this volatile market. AI valuation jitters sparked a Thursday sell-off — erasing a rally fueled by Nvidia's blowout quarter and upbeat guidance. Stocks moved higher after New York Fed President John Williams said he sees room for a near-term interest rate cut. You'll want to hear Cramer's reaction to Williams' comments. Bitcoin fell below $82,000, putting it on track for its worst month since 2022. Also in focus: Eli Lilly hits a $1 trillion market cap for the first time, commodities under pressure in wake of tariffs, "Faber Report" on Netflix, Comcast and Paramount Skydance submitting bids for Warner Bros. Discovery. Disclosure: Comcast is the parent company of NBCUniversal, which owns CNBC.Versant would become the new parent company of CNBC upon Comcast's planned spinoff of Versant. Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this informative episode, Dr. Jennie Berkovich is joined by experienced neurologists Dr. Palma and Dr. Lewis, Executive Medical Directors at Eli Lilly and Company. Our guests take this opportunity to share  their expert opinion and scientific understanding of Parkinson's disease and how we can anticipate medical interventions changing — possibly within our lifetimes. We explore how our genes, and genetic variants, can influence the onset, symptoms, and severity of Parkinson's disease. We address when genetic testing can be most helpful, who might be at higher risk, and how these discoveries are leading to potential new treatments and personalized care. Dr. Alberto Palma is Executive Medical Director, Early-Phase Development, Neurodegeneration Programs Lead at Eli Lilly and Company.Dr. Travis Lewis is Executive Medical Director at the Institute for Genetic Medicine at Eli Lilly and Company.Both are actively working on gene therapy clinical trials that aim to slow the progression of Parkinson's and its symptoms. DISCLAIMER: This video is sponsored by Eli Lilly and Company and hosted by JOWMA. It is intended for educational purposes only. The content in this video reflects treatment practices in the U.S.; please refer to your local guidelines for more information.Sponsor the JOWMA Podcast! Email admin@jowma.org   Become a JOWMA Member! www.jowma.org Follow us on Instagram! www.instagram.com/JOWMA_org Follow us on Twitter! www.twitter.com/JOWMA_med Follow us on Facebook! https://www.facebook.com/jowmaorg Stay up to date with JOWMA news! Sign up for the JOWMA newsletter! https://jowma.us6.list-manage.com/subscribe?u=9b4e9beb287874f9dc7f80289&id=ea3ef44644&mc_cid=dfb442d2a7&mc_eid=e9eee6e41e

Eli Lilly (LLY) became the 10th U.S. company to tap $1 trillion in market cap and has outperformed most of its peers, particularly its biggest rival, Novo Nordisk (NVO). Rick Ducat shows just how massive Eli Lilly's run is and highlights how the "red-hot" stock will have to build up its bullish base. He sees a breather on the horizon for the stock. Rick later turns to the options front to show where traders are pricing shares to move. ======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

From Wall Street to Main Street, the latest on the markets and what it means for your money. Updated regularly on weekdays, featuring CNBC expert analysis and sound from top business newsmakers. Anchored and reported by CNBC's Jessica Ettinger. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

Sandra Walker is CEO, Viacern Group, and Venture Partner at Hard Climate, a seasoned and inspirational pharma and biotech executive leading Commercial, Medical Operations and Excellence, Government Affairs, Global Strategy and Product Planning at companies such as Genentech, Roche, Eli Lilly and Abbvie. She delivered a state-of-the-art, candid, and intriguing keynote presentation that forces you to reflect on the language and process you use to make decisions in medicine, healthcare, and how you can challenge your current approaches and biases using neuroscience-based practical, real-world solutions to make bolder decisions with evidence to drive innovation forward.3:10 Speaker Introduction4:12 Turning Innovation into OutcomesThree Common recurring Decision PatternsExplaining Biases in Decision-makingPractical Solutions to Transform DecisionsThe Bolder WayDecision Audit5:56 Three Invisible Decision Patterns6:37 Status Quo Bias8:51 Countermoves You Can Use vs Status Quo Bias9:29 Confirmation Bias11:54 10-Minute Challenge Round To use Vs. Confirmation Bias 13:09 Completion Bias - Relief of Feeling Done16:30 Explaining the Brain under Pressure with Neuroscience 18:50 How to Quiet the Noise in BiasLabel the state – identify the bias, problem, riskExternalize thinking – move ideas onto paper to createpublic reasoningTeach the cheerleader to celebrate learning not justfinishing.Train for Learning not Finishing21:01 The Bolder Way - 6 steps to turn Awareness into ActionB - Bias and Blind Spots visualization (see the invisible)O - Observe: Disciplined CuriosityL - Learn: Broadened PerspectivesD - Decide with clarity and transparencyE - Empower: Trust with ContextR - Recalibrate: Boldness into Learning27:11 Bolder Way Framework Aligned to the Scientific Method 28:02 Language You Use is Key to Decision Outcome28:38 The Decision Audit to Deliver Clarity in 5 Minutes31:09 How Speed of Decision Impacts the Outcome

Timestamps:6:03 – Breakdown of FICO15:15 – Futures Trading Tip of the Week18:37 – Trump's $2K Tariff Plan34:46 – Burry's Shorts on NVDA & Palantir46:00 – What to Do After Becoming a Millionaire59:00 – Is Google the Sleeper AI Giant?1:04:10 – Holiday Market Play: Crypto or Stocks?1:08:20 – Trump x NVO x LLY Partnership Breakdown1:15:46 – Pre-Recession Indicators to Watch1:24:53 – CMG vs. CAVA Investment Outlook1:28:20 – End of Government Shutdown1:32:00 – Key Market Indicators for 20271:33:22 – Weekly Earnings RecapIn this week's Market Mondays, we break down everything from Trump's $2,000 plan to the future of AI and the latest market indicators signaling what's ahead for investors.We start with a deep dive into FICO scores and how they impact your financial future, then move into futures trading tips and Trump's bold plan to give every American $2,000 from tariff profits.We also discuss Michael Burry's short positions against Nvidia and Palantir, whether Google is the sleeper giant in AI, and what to do after you become a millionaire.Plus — we analyze Trump's new partnership with Novo Nordisk and Eli Lilly, what it means for biotech investors, and which markets — crypto or stocks — to focus on during the holiday season.As the government shutdown ends, we reveal key pre-recession indicators to watch, whether Chipotle (CMG) or CAVA are smart plays right now, and what signals could define the path to 2027.#MarketMondays #EarnYourLeisure #Investing #StockMarket #Crypto #FuturesTrading #TrumpEconomy #AIStocks #NVDA #Google #Palantir #NVO #LLY #FinancialEducation #WealthBuilding #RecessionPrep #EYLOur Sponsors:* Check out PNC Bank: https://www.pnc.com* Check out Square: https://square.com/go/eylSupport this podcast at — https://redcircle.com/marketmondays/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

[00:07:23] – The Black Committee: America's First Mass Surveillance ProgramBeito explains Senator Hugo Black's seizure of millions of private telegrams to spy on FDR's opponents — a little-known episode that prefigured today's surveillance state and “national security” abuses. [00:27:29] – The Newport Sex Scandal and FDR's Moral HypocrisyKnight and Beito expose Roosevelt's secret Navy operation that used entrapment to target suspected homosexual sailors — a scandal later erased from mainstream history. [00:39:31] – Going Off Gold: Roosevelt's Monetary RevolutionThe discussion covers how FDR's abandonment of the gold standard and arbitrary price-fixing launched America's age of fiat currency, inflation, and centralized economic manipulation. [00:49:16] – The “Fake News” Law That Almost HappenedBeito recounts a 1930s proposal to criminalize “false news” under FDR's influence — an early prototype of modern truth policing and digital censorship laws. [01:00:16] – The 72-Dose Childhood Vaccine LawsuitKnight reviews a lawsuit claiming the CDC never tested the combined safety of its full childhood vaccine schedule, arguing the agency hides behind untested assumptions of safety. [01:14:46] – Eli Lilly Bribery and Big Pharma CorruptionKnight reports on a Texas lawsuit accusing Eli Lilly of paying doctors to push high-profit drugs, tying it to systemic collusion between pharmaceutical giants and captured regulators. [01:24:23] – James Bradley on Vietnam: Precious FreedomAuthor James Bradley joins to discuss his book Precious Freedom, reframing the Vietnam War from the Vietnamese perspective and exposing decades of U.S. and media propaganda. [01:36:39] – Media Lies and CIA MythsBradley reveals how the U.S. and its allies fabricated the idea of “North and South Vietnam” as separate nations, a CIA-backed myth used to justify decades of warfare. [02:22:00] – Fourth Turning Politics and the Rise of Authoritarian SaviorsKnight and Bonta examine how historical cycles of crisis create conditions for strongmen like FDR, Trump, and others who exploit social chaos to centralize power. [03:02:17] – De-Dollarization and the End of U.S. Financial SupremacyBonta closes by warning that the weaponization of the dollar is accelerating the global shift toward BRICS and gold-backed trade systems, threatening the foundation of American economic dominance. Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silverFor 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHTFind out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

Three more suspects, including two affluent New Jersey teens, are now charged in a foiled ISIS-inspired Halloween terror plot, bringing the total to five. The FAA is cutting up to 10% of flights at 40 major airports as the government shutdown enters week six, triggering nationwide delays. President Trump announces a deal with Eli Lilly and Novo Nordisk to slash the cost of popular GLP-1 weight-loss drugs like Wegovy and Ozempic to about $350 through a new program called TrumpRX. Former House Speaker Nancy Pelosi, 85, announces she will not seek reelection after nearly four decades in Congress and two impeachments of President Trump. Geviti: Go to https://gogeviti.com/megynand get 20% off with code MEGYN. Walmart: Learn how Walmart is fueling the future of U.S. manufacturing at https://Walmart.com/America-at-work Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.